Existing Rabeximod can be used in Cyxone's planned Phase 2b study in patients with rheumatoid arthritis
Cyxone has analysed the Rabeximod that was previously manufactured by OxyPharma for clinical trials at Syntagon AB. Results show that the existing substance, despite having been stored for several years, can be used in Cyxone's upcoming Phase 2b study in patients with rheumatoid arthritis.Consequently, Cyxone does not believe that it is necessary to produce new batches of Rabeximod. This represents a considerable saving for the company and facilitates the start of the clinical programme. November 1, 2017 ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0)723 816168Email: